Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(2-(1h-benzo(d)imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
2. Daurismo
3. Glasdegib
4. Pf-04449913
1. 2030410-25-2
2. Pf-04449913 Maleate
3. Daurismo
4. Th2ev99s4z
5. 2030410-25-2 (maleate)
6. 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate
7. Glasdegib Maleate (jan)
8. Glasdegib Maleate [jan]
9. 1-((2r,4r)-2-(1h-benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleatesalt
10. Urea, N-((2r,4r)-2-(1h-benzimidazol-2-yl)-1-methyl-4-piperidinyl)-n'-(4-cyanophenyl)-, (2z)-2-butenedioate (1:1)
11. Pf 04449913 Maleate
12. Daurismo (tn)
13. Unii-th2ev99s4z
14. Chembl4297534
15. Schembl18171548
16. Dtxsid301027747
17. Glasdegib Maleate [who-dd]
18. Glasdegib Maleate [orange Book]
19. D11107
20. Pf-04449913 Maleate Salt, >=98% (hplc)
21. 1-((2r,4r)-2-(1h-benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate Salt
22. 1-[(2r,4r)-2-(1h-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea;(z)-but-2-enedioic Acid
Molecular Weight | 490.5 g/mol |
---|---|
Molecular Formula | C25H26N6O5 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 490.19646795 g/mol |
Monoisotopic Mass | 490.19646795 g/mol |
Topological Polar Surface Area | 171 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 714 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
L01XX63
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?